https://www.live-feeds.com/feed/fda-approves-new-use-of-popular-diabetes-drugContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-approves-new-use-of-popular-diabetes-drughttps://www.live-feeds.com/feed/fda-approves-new-use-of-popular-diabetes-drug#u57240Fri, 04 Sep 2026 18:53:16 +0000The FDA approved Eli Lilly's Mounjaro to reduce major adverse cardiovascular event risks for high-risk adults with type 2 diabetes. While this expands the drug's clinical utility, Eli Lilly is now fighting a booming black market for retatrutide, an experimental injectable that outperformed previous obesity medications in clinical trials. This development occurs as GLP-1 use increases among U.S. children under 12 despite a lack of FDA approval. Access remains limited for some patients due to high costs and specific medical disqualifications within the Medicare Bridge pilot program.Why https://www.live-feeds.com/feed/fda-approves-new-use-of-popular-diabetes-drughttps://www.live-feeds.com/feed/fda-approves-new-use-of-popular-diabetes-drug#u56299Fri, 04 Sep 2026 01:46:14 +0000The FDA approved Eli Lilly's Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who face high risk for such events. This approval strengthens Eli Lilly's position in negotiations with employers and insurers as GLP-1 drug coverage declines toward 2027. While the drug's utility expands, patient access remains a hurdle; some patients cannot afford the monthly costs of related drugs like Zepbound, and the Medicare Bridge pilot program excludes certain eligible individuals based on specific medical disqualifications.Why it m https://www.live-feeds.com/feed/fda-approves-new-use-of-popular-diabetes-drughttps://www.live-feeds.com/feed/fda-approves-new-use-of-popular-diabetes-drug#u54194Wed, 02 Sep 2026 00:51:58 +0000The FDA has approved Eli Lilly's Mounjaro (tirzepatide) for a new use to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes. This expansion targets patients who are at high risk for cardiovascular events. The approval provides Eli Lilly with a strategic advantage in negotiations with insurers and employers at a time when coverage for GLP-1 drugs is declining heading into 2027.Why it mattersMounjaro belongs to a class of GLP-1 drugs used for diabetes and weight management. This new indication allows the drug to be marketed specifically for heart health ra